View Post

TAILORx High-Risk Group Analysis Adds to Oncotype DX Chemo-Prediction Data

In Clinical Trials by Barbara Jacoby

By: Staff Reporter From: genomeweb.com In secondary analysis of data from the TAILORx trial, researchers have added new confirming evidence that patients with high risk scores from Genomic Health’s Oncotype DX appear to benefit significantly from added chemotherapy. Investigators led by the trial’s PI Joseph Sparano shared their findings in JAMA Oncology today and also presented the analysis at the …

View Post

Study Finds Breast, Ovarian Cancer Gene Tests Cost-Effective for Unselected Breast Cancer Patients

In In The News by Barbara Jacoby

By: Staff Reporter From: genomeweb.com Health systems in the UK and US could cost-effectively screen all women with breast cancer for risky germline changes in a handful of breast or ovarian cancer genes, according to a new economic modeling analysis, identifying at-risk individuals who could benefit from additional imaging tests and cancer-reducing interventions. “[T]he costs of testing falling … can …

View Post

Liquid Biopsy Assay From MSKCC Approved by New York State

In In The News by Barbara Jacoby

By: Staff Reporter From: genomeweb.com Memorial Sloan Kettering Cancer Center said today that New York state has approved the center’s liquid biopsy test for noninvasive cancer genomic profiling and disease monitoring. The test, called Analysis of Circulating cfDNA to Evaluate Somatic Access (MSK-ACCESS), has been clinically validated and implemented by MSK’s molecular diagnostics service. It sequences 129 cancer-associated genes selected …

View Post

Another Scammer Warning

In In The News by Barbara Jacoby

From: genomeweb.com Health officials in the US have issued a fraud alert for a scam involving genetic testing that is targeting seniors, Bloomberg reports. Sheila Davis, a US Department of Health and Human Services Office of the Inspector General spokesperson, tells Bloomberg that people are being targeted through telemarketing, booths at public events, health fairs, and even door-to-door visits. The …

Agendia’s MammaPrint & BluePrint Tests for Breast Cancer Highlighted at Personalized Medicine Conference

In In The News by Barbara Jacoby

Molecular subtyping provides a more precise prognosis and valuable guidance about the best treatment for early-stage breast cancer, according to a presentation by Neil Barth, M.D., at the prestigious Personalized Medicine World Conference (PMWC). Dr. Barth, a medical oncologist and Chief Medical Officer of Agendia, was a featured speaker at the recently concluded conference. Agendia’s BluePrint® molecular diagnostics assay is …